Top Tech Companies (2,065)
Don't see your company?
Create a company profile
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases.
Fluxergy was founded 10 years ago with a vision to democratize the world of laboratory testing, by making testing more accessible and affordable. Fluxergy’s platform technology enables us to understand our world and our health in ways that were never possible before. Fluxergy is developing a platform with multi-modal detection technologies which bring the variety of tests found in the central lab to the palm of your hand – This includes molecular testing like PCR, Immunochemistry and chemistry testing, and microscopy testing such as cytometry. Fluxergy’s platform vision is the detection of genes, proteins, small molecules, and cells with the same analyzer. The automated, sample-to-answer workflows can be customized for specific sample and testing methods.
As a world-leading drug device combination solutions specialist, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy. We are the utmost holistic partner and help our customers succeed in the sprint to market. From early device strategy to state-of-the-art manufacturing, we're committed to the highest quality standards. Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission. Nemera’s services and products cover five key delivery routes: ● Ophthalmic (preservative-free multidose eyedroppers) ● Nasal, Buccal, Auricular (pumps, valves and actuators for sprays), ● Inhalation (pMDI, DPIs) ● Dermal and Transdermal (airless & atmospheric dispensers) ● Parenteral (auto-injectors, pens, safety devices & implanters) At Nemera, we put patients first when designing, developing and manufacturing drug delivery devices because we know that accurate dosing and ergonomics contribute to patients completing their treatment. Whether they are Nemera proprietary or customer owned, our devices receive the utmost care because we know how critical they are for patients’ health and well-being. Interested in joining a team that truly enjoys working together and prides itself on being at the forefront of innovation and quality? Do you always go the extra mile to deliver on your commitments? Want to feel proud of your work because it improves patients’ lives? If you're ready to help us grow our business and make a real difference, please visit https://www.nemera.net or contact us at [email protected].
Landmark Bio is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing technologies for the new generation of medicines to come. Founding partners include Harvard University, Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies (FDB), and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Mass General Brigham, and the Dana-Farber Cancer Institute. For more information please contact [email protected]
Valspec is the leading provider of computer system validation and system life cycle (SLC) services including the testing, commissioning and qualification of manufacturing automation and IT systems. Valspec was established with a mission to meet the wide spectrum of services that help our clients meet their goals. Our proven history in plant automation and engineering services has allowed us to branch out and be highly effective in meeting a variety of project and resource needs. We look for passionate engineers like yourself who are looking to: •Be an innovator •Work with the best and brightest •Build the career you want •Work for a company you can be proud of Many of the projects that we work on assure that life-changing drugs are available to those who need them. Other projects have a goal of streamlining production to meet demand at a lower cost so that the drug companies have the means to discover new life saving therapies.
We exist to ensure all patients have access to early cardiac and pulmonary disease detection and high quality care that improves and extends their lives. We believe the ability to listen is the ability to care. Which is why we’re dedicated to providing healthcare professionals with industry leading digital tools to hear and understand their patients’ hearts and lungs — allowing them to detect with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Hear clearly. Care confidently.
Founded in Indianapolis in 2014, Genezen is focused on supporting the demands of the current and future gene and cell therapy manufacturing market worldwide— making viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen offers early-phase process development, GMP lentiviral vector production, retroviral vector production, and analytical testing services, building on the company's expansive knowledge and experience in the industry and working with the nation's leading institutions. For more information, or to learn more about services offered in Genezen's new cGMP facility, please visit our website: www.genezen.com
WattGlass is a startup company based in Fayetteville
Vascular Perfusion Solutions develops medical devices designed to preserve and resuscitate vascularized organs.
Uqora is a biotechnology company focused on urinary tract health. Uqora has developed innovative solutions for proactive urinary health.
Gatehouse Bio is developing therapeutics that correct the effects of disease-driving mutations in small RNA genes. We believe there is an RNA code that can treat every disease. Our mission is to find that code and use it to develop effective therapeutics. Our platform is the first to use AI to discover small RNA mutations and design oligonucleotides that crack a disease’s code. Our pipeline and partnerships are focused on developing drugs for therapeutic areas with known heterogeneity such as fibrosis, inflammation and neurodegeneration. With every single code we break, we unlock the potential to improve the lives of many.
Indica Labs is the world’s leading provider of computational pathology software and services. Our flagship HALO® image analysis platform enables fast, quantitative evaluation of tissues using a broad range of artificial intelligence (AI) and computer vision algorithms. HALO Link™ and HALO AP™ facilitate remote image analysis, collaboration and management. Through a combination of precision, performance, scalability, and usability our software solutions enable pharmaceutical companies, diagnostic labs, research organizations, and Indica’s own contract pharma services team to advance tissue-based research, clinical trials, and diagnostics. Indica Labs is proudly located in Albuquerque, New Mexico. Drawing from the rich pool of local talent, our software development and IT support team are experts in their respective fields. including image analysis, artificial intelligence, web development, databases, network architecture and security. To support our customers, we have experienced PhD-level application scientists and pharma services team members based in locations across the US, Europe, Japan and China who are ready to assist you. Our single mission is to help customers extract the most useful data from their digital pathology.
Nielsen BioSciences is a biotechnology company .
Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease
NeoTherma Oncology is a Bioelectric device developer.
Gentueri works with laboratories to improve the quality of results and laboratory efficiency.
Combining development of clinical genetic assays on a patented technology platform with next generation sequencing for clinical testing
Joywell Foods is developing the first healthy, protein sweeteners.
Triad Life Sciences® is a science-driven, patient-focused biotech company dedicated to the innovation of tissue-based solutions for the treatment of acute or chronic wounds, soft tissue injuries, and other regenerative applications. Triad is diligent in its commitment to providing best-in-class solutions to address inherent problems with Extracellular Matrixes (ECMs) through our breakthrough material science platform. To achieve this unique value proposition, we focus on delivering the products that are: • Innovative. Triad maximizes today’s ECM technology to develop best-in-class products and programs while simultaneously advancing science to break through today’s barriers and create the most innovative products, programs and life-improving solutions for the future. • Reliable. Triad reduces or eliminates known material variance through stringent material selection and proprietary processing technology, thereby providing our customers with the most consistently reliable and best-in-class products possible. • Affordable. Triad increases patient access to our best-in-class solutions by partnering with our customers to develop pricing strategies and programs that best fit the specific needs across a broad spectrum of care givers and their patients.
Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. We bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them most.
